Drawing for ZYGEL

USPTO serial 87571145

ZYGEL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BEN, LINDSEY HEATHER
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ZYGEL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sarah Anne Keefe

Sarah Anne Keefe Womble Bond Dickinson (US) LLP470 Atlantic Avenue, Suite 600Independence WharfBOSTON, MA 02210

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Mar 7, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Mar 7, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 13, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 12, 2021EX5GSOU EXTENSION 5 GRANTED—
Jul 8, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 30, 2021EXT5SOU EXTENSION 5 FILED—
Jun 30, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 6, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 4, 2021EX4GSOU EXTENSION 4 GRANTED—
Jan 4, 2021EXT4SOU EXTENSION 4 FILED—
Jan 4, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 10, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 8, 2020EX3GSOU EXTENSION 3 GRANTED—
Jun 8, 2020EXT3SOU EXTENSION 3 FILED—
Jun 8, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 30, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 28, 2020EX2GSOU EXTENSION 2 GRANTED—
Jan 28, 2020EXT2SOU EXTENSION 2 FILED—
Jan 28, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 23, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 19, 2019EX1GSOU EXTENSION 1 GRANTED—
Jul 19, 2019EXT1SOU EXTENSION 1 FILED—
Jul 19, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 29, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 12, 2018TMBNTTAB RELEASE CASE TO TRADEMARKS—
Dec 12, 2018OP.TOPPOSITION TERMINATED NO. 999999—
Dec 12, 2018OP.DOPPOSITION DISMISSED NO. 999999—
Apr 25, 2018OP.IOPPOSITION INSTITUTED NO. 999999—
Feb 14, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 31, 2018DOCKASSIGNED TO EXAMINER—
Jan 25, 2018ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 26, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 26, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 6, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 6, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 6, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 20, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 20, 2017DOCKASSIGNED TO EXAMINER—
Aug 22, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 21, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance